Social Media Ideas for Fennec Pharmaceuticals

Fennec Pharmaceuticals Reports Hearing Loss Reduction With Pedmark in Japan Phase 2 Trial

Data from the Phase 2 STS-J01 trial presented at SIOP 2026 show that Fennec Pharmaceuticals’ Pedmark significantly reduced cisplatin-related hearing loss in pediatric and AYA patie...

<![CDATA[FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A]]>

Faron Pharmaceuticals receives major holding notification

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Anonymous (not verified) Sat, 09/19/2026 - 21:55 field_thread_url https://cafepharma.com/boards/threads/aurinia-pharmaceuticals.652...

Pharmacosmos Therapeutics

Pharmacosmos Therapeutics Anonymous (not verified) Fri, 10/16/2026 - 10:12 field_thread_url https://cafepharma.com/boards/threads/pharmacosmos-therapeutics...

<![CDATA[Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million ]]>

Fenix Resources Limited (FEXRF) Q4 2026 Earnings Call Transcript

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to “determine next steps” for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update...

<![CDATA[Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifyin...

<![CDATA[Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing ]]>

Alkem Laboratories launches NeuCeno for partial-onset seizures in adults

The once-daily oral therapy is available in five strengths, with clinical studies showing reductions in seizure frequency among adults with uncontrolled focal seizures

Kiniksa

Kiniksa Anonymous (not verified) Thu, 09/17/2026 - 18:54 field_thread_url https://cafepharma.com/boards/threads/kiniksa.658756/ board na...

Kiniksa

Kiniksa Anonymous (not verified) Mon, 10/05/2026 - 04:07 field_thread_url https://cafepharma.com/boards/threads/kiniksa.658756/ board na...

Jaguar Health Receives Fee Waivers from FDA

Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for...

<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...

Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency

<![CDATA[Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909]]&gt...

<![CDATA[Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data]]>

Pharming wins approval of Joenja for younger age group

<![CDATA[Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion ]]>

Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder

Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare d...

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...